Home › Compare › DTCFF vs SBUX

DTCFF vs SBUX: Dividend Comparison 2026

DTCFF yields 500.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTCFF wins by $61399.36M in total portfolio value
10 years
DTCFF
DTCFF
● Live price
500.00%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61399.52M
Annual income
$44,063,578,515.70
Full DTCFF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — DTCFF vs SBUX

📍 DTCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTCFFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTCFF + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DTCFF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTCFF
Annual income on $10K today (after 15% tax)
$42,500.00/yr
After 10yr DRIP, annual income (after tax)
$37,454,041,738.34/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, DTCFF beats the other by $37,453,981,272.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTCFF + SBUX for your $10,000?

DTCFF: 50%SBUX: 50%
100% SBUX50/50100% DTCFF
Portfolio after 10yr
$30699.85M
Annual income
$22,031,824,826.08/yr
Blended yield
71.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

DTCFF
No analyst data
Altman Z
-31.5
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTCFF buys
0
SBUX buys
0
No recent congressional trades found for DTCFF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTCFFSBUX
Forward yield500.00% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$61399.52M ✓$167.0K
Annual income after 10y$44,063,578,515.70 ✓$71,136.45
Total dividends collected$59892.67M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: DTCFF vs SBUX ($10,000, DRIP)

YearDTCFF PortfolioDTCFF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$60,700$50,000.00$11,121$420.68+$49.6K → DTCFF
2$348,594$283,644.86$12,548$648.40+$336.0K → DTCFF
3$1,895,372$1,522,376.89$14,440$1,013.98+$1.88M → DTCFF
4$9,763,990$7,735,942.00$17,068$1,617.30+$9.75M → DTCFF
5$47,691,977$37,244,507.54$20,912$2,649.52+$47.67M → DTCFF
6$221,049,019$170,018,603.23$26,875$4,499.29+$221.02M → DTCFF
7$972,993,924$736,471,474.07$36,771$8,014.12+$972.96M → DTCFF
8$4,070,762,075$3,029,658,575.98$54,542$15,197.11+$4070.71M → DTCFF
9$16,201,818,371$11,846,102,950.68$89,602$31,242.49+$16201.73M → DTCFF
10$61,399,524,173$44,063,578,515.70$167,011$71,136.45+$61399.36M → DTCFF

DTCFF vs SBUX: Complete Analysis 2026

DTCFF — Stock

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full DTCFF Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this DTCFF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTCFF vs SCHDDTCFF vs JEPIDTCFF vs ODTCFF vs KODTCFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.